These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32727989)

  • 1. Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab.
    Nakashima K; Demura Y; Oi M; Tabata M; Tada T; Shiozaki K; Akai M; Ishizuka T
    Intern Med; 2020 Dec; 59(23):3055-3059. PubMed ID: 32727989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer.
    Nakamura M; Otsuka T; Hayashi R; Horita T; Ota M; Sakurai N; Takano H; Hayashi T; Kumagai M; Yamada S; Arisawa T
    Intern Med; 2020 Nov; 59(21):2711-2717. PubMed ID: 32669493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durvalumab boosts progression-free survival in NSCLC.
    Gourd E
    Lancet Oncol; 2018 Jan; 19(1):e11. PubMed ID: 29175147
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.
    Ortega Sanchez G; Jahn K; Savic S; Zippelius A; Läubli H
    J Immunother Cancer; 2018 Sep; 6(1):85. PubMed ID: 30176946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Course of Preexisting Uveitis during Treatment of Lung Cancer with Durvalumab.
    Ahmad TR; Doan T; Gonzales JA; Acharya NR; Tsui E
    Ocul Immunol Inflamm; 2020 May; 28(4):566-570. PubMed ID: 31710511
    [No Abstract]   [Full Text] [Related]  

  • 8. Durvalumab for the treatment of non-small cell lung cancer.
    Murakami S
    Expert Rev Anticancer Ther; 2019 Dec; 19(12):1009-1016. PubMed ID: 31782989
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report.
    Yorozuya T; Taya T; Yasuda K; Nagano Y; Shioya M; Chiba H; Takahashi H
    Thorac Cancer; 2020 Apr; 11(4):1090-1093. PubMed ID: 32045109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
    Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
    Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer.
    Davies M; Duffield E
    Clin J Oncol Nurs; 2020 Jun; 24(3):277-283. PubMed ID: 32441679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report.
    Makiguchi T; Tanaka H; Kamata K; Taima K; Kurose A; Tasaka S
    Thorac Cancer; 2021 Oct; 12(20):2811-2814. PubMed ID: 34405563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
    Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of a patient with non-small cell lung cancer and interstitial lung disease with durvalumab: a case report.
    Tao H; Li F; Li R; Han X; Hu Y
    Ann Palliat Med; 2020 Sep; 9(5):3623-3628. PubMed ID: 32648466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
    Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer.
    Shaverdian N; Offin MD; Rimner A; Shepherd AF; Wu AJ; Rudin CM; Hellmann MD; Chaft JE; Gomez DR
    Radiother Oncol; 2020 Mar; 144():101-104. PubMed ID: 31786421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durvalumab-induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non-small cell lung cancer: A case report.
    Domblides M; Geier M; Decroisette C; Descourt R
    Thorac Cancer; 2021 Apr; 12(8):1240-1243. PubMed ID: 33624409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil.
    Sato K; Inoue J; Ninomiya M; Iwata T; Sano A; Tsuruoka M; Onuki M; Sawahashi S; Ouchi K; Masamune A
    Clin J Gastroenterol; 2023 Oct; 16(5):720-725. PubMed ID: 37480423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Bronchopleural Fistula After Durvalumab Consolidation for Stage III Non-Small-Cell Lung Cancer.
    Darwin A; Rose T; Tandon A; Tanvetyanon T
    Clin Lung Cancer; 2021 Jan; 22(1):e18-e24. PubMed ID: 32828661
    [No Abstract]   [Full Text] [Related]  

  • 20. Bullous Pemphigoid Associated With a New Combination Checkpoint Inhibitor Immunotherapy.
    Fontecilla NM; Khanna T; Bayan CY; Antonov NA; Geskin LJ
    J Drugs Dermatol; 2019 Jan; 18(1):103-104. PubMed ID: 30681807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.